

Application No.: 10/699,563

Docket No.: 5998-0506PUS3

Docket No.: 5998-0506PUS3  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Bradford Van Wagenen et al.

Application No.: 10/699,563

Confirmation No.: 1604

Filed: November 3, 2003

Art Unit: 1625

For: **HETEROPOLYCYCLIC COMPOUNDS AND  
THEIR USE AS METABOTROPIC  
GLUTAMATE RECEPTOR ANTAGONISTS**

Examiner: Z. N. Davis

**ASSENT OF ASSIGNEES TO INVENTORSHIP CORRECTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This letter is filed as part of a petition under 37 C.F.R. § 1.48(a). The above-identified application is assigned to the following two entities:

First Assignee: NPS PHARMACEUTICALS, INC.

Address: 383 Colorow Drive  
Salt Lake City, UT 84108 USA

Second Assignee: ASTRAZENECA AB

Address: Global Intellectual Property  
SE-151 85 Södertälje, Sweden

A first Assignment by the original inventors to NPS Pharmaceuticals in the parent application USSN 10/076,618 was recorded at Reel 012758 / Frame 0798. Copies of two other executed assignments by newly added inventors and assigning 50% to AstraZeneca AB are also attached.

The Assignees hereby assent to the correction of inventorship described in a Petition to Add Inventors filed with a Request for Continued Examination on December 6, 2005.

<b>I. NAMES AND SIGNATURES OF ASSIGNEES</b>		
AstraZeneca AB	By: <i>J. H. Hasslev</i> Name: Bo Hasslev Title: Director IP Finance & IS	Date: <i>31 Jan 2006</i>
<b>II. NAMES AND SIGNATURES OF WITNESSES</b>		
Name:	Signature:	Date:
Name:	Signature:	Date:

<b>III. NAMES AND SIGNATURES OF ASSIGNEES</b>		
NPS Pharmaceuticals, Inc.	By: _____ Name: Title:	Date:
<b>IV. NAMES AND SIGNATURES OF WITNESSES</b>		
Name:	Signature:	Date:
Name:	Signature:	Date: